New Healthcare market report from Business Monitor International: "Kazakhstan Pharmaceuticals & Healthcare Report Q3 2012"
Boston, MA -- (SBWIRE) -- 08/16/2012 -- BMI View: Kazakhstan continues to stand out among the pharmaceutical markets of Central Asia in terms of openness to foreign investment in the pharmaceutical industry. The country's expected accession to the World Trade Organisation could come as early as the end of 2012 and this will continue to drive improved market regulation and intellectual property protections. The acquisitions of leading local players Chimpharm and Global Pharm by foreign players represent a positive assessment of the marketplace. The government has recently reiterated its commitment to producing 50% of all medicines domestically by 2014, a goal that appears very difficult to reach unless significant new capacity comes on line within the next 18 months. In macro terms, Kazakhstan's primary weakness remains the apparent absence of a clear transition process for when President Nursultan Nazarbayev leaves office. Relatively small but significant bouts of social unrest and terrorism over the last 12-18 months hint at the potential for deeper problems in the future.
View Full Report Details and Table of Contents
Headline Expenditure Projections
- Pharmaceuticals: KZT195.8bn (US$1.34bn) in 2011 to KZT220.8bn (US$1.49bn) in 2012; up 12.7% in local currency terms and 11.7% in US dollar terms. US dollar forecast downgraded due to updated exchange-rate forecasts.
- Healthcare: KZT1,043.5 (US$7.11bn) in 2011 to KZT1,182.2 in 2012; up 13.3% in local currency terms and 12.3% in US dollar terms. Forecast downgraded due to macroeconomic factors and lower exchange-rate projections.
- Medical devices:KZT86.51bn (US$590mn) in 2011 to KZT94.51bn (US$639mn) in 2012; up 9.3% in local currency terms and 8.3% in US dollar terms. Forecast downgraded due to macroeconomic factors and lower exchange-rate projections.
Risk Reward Rating: Kazakhstan ranks 16th this quarter in BMI's Risk Reward Ratings (RRR) for Central and Eastern Europe (CEE). Downsides for the market include its relatively small population and challenging geography, as well as political uncertainty and exposure to the commodity cycle. Corruption and, potentially, social tensions linked to inequality and uneven development remain major challenges. Upsides include the country's likely imminent WTO accession and major commitments to state spending on healthcare, as well as a clear commitment to long-term regulatory reform and harmonisation with key international standards and practices.
Key Trends And Developments
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Turkey Pharmaceuticals & Healthcare Report Q3 2012
- Algeria Pharmaceuticals & Healthcare Report Q3 2012
- Egypt Pharmaceuticals & Healthcare Report Q3 2012
- Taiwan Pharmaceuticals & Healthcare Report Q3 2012
- Romania Pharmaceuticals & Healthcare Report Q3 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Zimbabwe Pharmaceuticals & Healthcare Report Q3 2012
- Oman Pharmaceuticals & Healthcare Report Q3 2012
- Nigeria Pharmaceuticals & Healthcare Report Q3 2012